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Abstract
Background: Little evidence exists to guide treatment of alopecia areata (AA). The current
practices in treatment of children compared to adults and of progressive stages of hair loss are
unknown. The objective of this study was to examine the current practices of southeastern United
States dermatologists for the treatment of AA.
Methods: Dermatologists were sent anonymous questionnaires regarding their treatment
practices by mail. Respondents' frequencies of treatment in children compared to adults and in
patchy hair loss compared to widespread hair loss were compared with Wilcoxon signed-ranks
tests and Friedman tests. As a secondary source, the National Alopecia Areata Registry (NAAR)
database was analyzed for patients' treatment histories.
Results: Survey results suggested that dermatologists recommend treatment less frequently for
children than adults and for more advanced hair loss. NAAR data confirmed that offering no
treatment for AA is relatively common.
Conclusion: Dermatologists' treatment of AA is inconsistent. A stronger evidence base will
provide more consistent treatment options.
Background
Alopecia areata (AA) is relatively common, accounting for
2% of new dermatology outpatient visits in the United
States and the United Kingdom [1], but little is yet known
about optimal treatment of the disease. Many AA treat-
ments, including topical, intralesional and oral corticos-
teroids, minoxidil, contact sensitizers, anthralin, and
PUVA [2], have not been critically evaluated. Though
treatments such as corticosteroids have been commonly
used with reported success for years, only rarely have AA
treatments been thoroughly evaluated in randomized
controlled trials; these trials have often been limited in
scope and have demonstrated little benefit [3]. Notably,
intralesional corticosteroid treatment, one of the most
Published: 12 November 2009
BMC Dermatology 2009, 9:11 doi:10.1186/1471-5945-9-11
Received: 1 October 2008
Accepted: 12 November 2009
This article is available from: http://www.biomedcentral.com/1471-5945/9/11
© 2009 Mukherjee et al; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.Page 1 of 8
(page number not for citation purposes)
BMC Dermatology 2009, 9:11 http://www.biomedcentral.com/1471-5945/9/11commonly used AA treatments [4], has never been evalu-
ated in a randomized controlled trial [3].
In the absence of a strong evidence base, treatment guide-
lines that stratify patients by age and disease extent have
been proposed [5-7]. These guidelines recommend intral-
esional steroids as first line therapy for patch hair loss in
adults. They generally do not recommend painful or more
aggressive treatments for children under 10. Because alo-
pecia totalis (AT) and universalis (AU) are more difficult
to treat than patch hair loss, they suggest that physicians
consider the option of no medical treatment. It is impor-
tant to note that the patient's desire for treatment of this
disorder cannot be overestimated.
Without firm treatment guidelines, the current AA treat-
ment practices of dermatologists vary greatly. The 1990-
2000 National Ambulatory Medical Care Survey
(NAMCS) indicated that topical and intralesional triamci-
nolone were the most commonly prescribed AA treat-
ments, followed by augmented betamethasone
propionate and minoxidil [4]. However, the NAMCS
results do not provide the most commonly used AA treat-
ments stratified by patient age or disease severity. The cur-
rent practices in treatment of children compared to adults
and of progressive stages of hair loss remain unknown.
The aim of this study was to examine the current practices
of southeastern United States dermatologists for the treat-
ment of AA. We surveyed dermatologists in the region by
mailed questionnaire, and we compared dermatologist-
reported treatment preferences to patient-reported treat-
ment data obtained from the National Alopecia Areata
Registry. Reported in this article are the results of our sur-
vey and subsequent analyses.
Methods
This study was approved by the Institutional Review
Board of the University of North Carolina (UNC) School
of Medicine (Study #07-1872, approved November 13,
2007).
Survey Administration
A mailing list of 1888 dermatologists in the southeastern
United States (Virginia, North Carolina, South Carolina,
Georgia, and Florida) was obtained from the American
Academy of Dermatology (December 3, 2007). The list
included all members of the Academy, including those
with military addresses, in the region. In January 2008,
dermatologists were sent anonymous surveys regarding
their preferences for treatment of AA and a cover letter by
the investigators by U.S. Postal Service. Postage-paid enve-
lopes were included for responses. Topics included:
• Frequency of recommending any medical treatment
(choices: all/most/some/none of the time) for chil-
dren/adults with first episode patch hair loss/multiple
episodes patch loss/alopecia totalis (AT)/alopecia uni-
versalis (AU),
• Choice of treatment for children/adults with first
episode patch hair loss/multiple episodes patch loss/
AT/AU,
• Use of wigs and eyebrow tattoos,
• Barriers to use of individual treatments, and
• Physician demographics.
Children were defined as "preadolescents" in the survey,
which was developed by the authors and was piloted and
evaluated for clarity with UNC-Chapel Hill dermatology
residents. A copy of the survey is included as a supplement
to this article [see Additional file 1].
Surveys were not sent to the UNC-Chapel Hill Dermatol-
ogy faculty. Surveys completed by physicians who indi-
cated that they did not practice general dermatology in the
United States were excluded from analysis.
Analyses of Survey Data
For the purpose of analysis of the survey data, it was
assumed that first episode of patch hair loss, multiple epi-
sodes of patch hair loss, AT and AU are forms of the same
condition with increasing degrees of severity.
For analysis of frequency of treatment, Wilcoxon signed-
ranks test procedures were used when comparing
respondents' treatment of children compared to adults,
and Friedman test procedures (nonparametric repeated
measures comparisons) were used when comparing
respondents' treatment of the four AA stages of disease.
Each Friedman test was followed by pairwise comparisons
of disease stages using Dunn's multiple comparisons test.
For analysis of frequency of individual medication usage,
McNemar's test was used when comparing respondents'
treatment of children compared to adults. In the applica-
tion of these test procedures, respondents who had
answered with "Not Applicable (I do not see this kind of
patient)" for one or more of the groups being compared
were excluded from the analysis.
Exploratory analyses using Mann-Whitney tests were per-
formed to investigate whether certain demographic char-
acteristics of the respondents were predictive of the
frequencies of treatments.Page 2 of 8
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ues obtained were used for purposes of generating
hypotheses and should not be treated as confirmatory.
Because the purpose of analysis was hypothesis genera-
tion rather than hypothesis confirmation, adjusting for
multiple comparisons was not necessary.
National Alopecia Areata Registry (NAAR) Data
Patient treatment histories retrieved from the National
Alopecia Areata Registry http://www.mdanderson.org/
departments/alopecia/ served as a complementary second
source of information. Patients who donated DNA to the
registry completed a "long form" that recorded their cur-
rent and previous treatments as well as disease classifica-
tion. Patients were classified by overall (lifelong) disease
severity into four categories: transient alopecia areata
(AAT), patchy alopecia areata (AAP), alopecia totalis (AT),
and alopecia universalis (AU). Within each AA category,
the registry database was analyzed for number of
instances in which a patient had previously received or
was currently receiving a certain treatment. A total of 1264
patients had completed the long form at the time when
the database was analyzed.
Analyses of NAAR Data
Within each disease stage, the number of database men-
tions of a particular drug category was divided by the
number of patients with that stage of disease to produce a
"drug category mentions per patient" ratio.
For each category of medications, the number of men-
tions per patient was assumed to follow a Poisson distri-
bution in each of the patient strata defined by disease
stage. In the special case of the medication category
"None", we assumed that each patient can contribute to
the count of mentions of "None" no more than one time.
Consequently, a binomial distribution was assumed for
this special category. Under these assumptions, the sum-
mary totals available from the registry were sufficient for
the fitting of the desired generalized log-linear model for
Poisson regression and for fitting the desired binomial
model. These models were fitted separately for each cate-
gory of medication (11 separate models). For each, the
results of fitting the model were used to test the overall
null hypothesis "no difference among the 4 disease-stage
strata". For the overall tests that were statistically signifi-
cant at level α = 0.005, pairwise comparisons between
strata were examined and statistical tests of size α = 0.01
were performed. Thus, a difference between two strata for
a given category of medication was considered statistically
significant if both the overall test p-value was smaller than
0.005 and the pairwise test p-value was smaller than 0.01.
Results
Survey
Of the 1870 surveys mailed, 313 surveys (16.7%) were
returned. Out of those, 44 surveys were excluded from fur-
ther analysis because they were completed by retired der-
matologists, administrators, or non-practicing physicians.
The remaining 269 surveys were completed by respond-
ents who indicated that they practiced general dermatol-
ogy in the United States at the time of survey. Thus, the
response rate from this target population was 14.7%
(269/1826).
Respondents recommended medical treatment in adults
more frequently than in children [see Additional file 2:
Table S1]. This tendency was notably evident for patch
hair loss (first or multiple episodes) and weakly evident
for AT and AU. For both adults and children, comparisons
of disease stages showed that multiple episodes patch hair
loss was treated more frequently than AT (results of Fried-
man tests not shown).
Respondents' choices of medications for treatment of chil-
dren and adults were notable for increased systemic corti-
costeroid usage with increasing disease severity and
frequent usage of topical and intralesional corticosteroids,
anthralin, and minoxidil [see Additional file 3: Table S2].
Topical and intralesional steroids were used more fre-
quently for multiple episodes patch hair loss than AT,
while systemic corticosteroids were used less frequently
for multiple episodes patchy hair loss than AT [see Addi-
tional file 3: Table S2].
Usage of the most commonly recommended medications
(topical, intralesional, and systemic corticosteroids and
minoxidil) was evaluated in children compared to adults.
Topical corticosteroids were used more frequently for
patch hair loss in children than adults; intralesional and
systemic corticosteroids and minoxidil were used more
frequently in adults than children for all four disease
stages [see Additional file 4: Table S3].
In a free response box on the survey, respondents listed
other treatments that they used for AA that were not pro-
vided as response options (Table 1). The most commonly
mentioned treatments were calcineurin inhibitors (73
mentions).
Of those respondents who reported seeing scalp hair loss
in their practice (N = 260), 12% recommended wigs all or
most of the time; 80% some of the time; and 6% none of
the time. Of those who reported seeing eyebrow loss (N =
239), 7% recommended temporary or permanent eye-
brow tattoos all or most of the time; 45% some of the
time; and 48% none of the time.Page 3 of 8
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various treatments of AA were the risk of side effects when
using systemic corticosteroids and methotrexate, pain
associated with intralesional corticosteroids, and time
commitment and cost of PUVA/UVB therapy [see Addi-
tional file 5: Table S4]. Other frequently cited barriers
were patient age when using intralesional corticosteroids
and lack of experience with topical immunotherapy and
methotrexate. Lack of supporting evidence and non-FDA
approval were not commonly cited as barriers to any treat-
ment.
Most respondents indicated that they did not practice a
dermatologic subspecialty, and a large number of
respondents saw less than two new AA patients monthly
(of which 25% or less were children) and practiced in sub-
urban areas (Table 2). Earlier in the analysis, AT was
found to be the "critical point" of disease severity at which
treatment frequency began to drop; thus, certain demo-
graphic divisions, specifically male versus female gender,
0-2 versus 3 or more new AA patients per month, and 0-5
versus 6 or more years in practice, were compared in terms
of frequency of treatment of AT in adults. No differences
were found in frequency of treatment of AT between these
demographic divisions (data not shown). Additionally,
no substantial differences were found in frequency of
treatment of AT in children in those practices in which ≤
25% and > 25% of new AA patients were children.
National Alopecia Areata Registry
Treatment data from the NAAR showed that over 10% of
patients in each AA disease category reported having
received no treatment over the course of their disease (Fig-
ure 1). Though there was a trend towards AU patients
receiving no treatment most often (15.7%), there was no
statistically significant difference between disease stages
in the percentage of patients receiving no treatment (p =
0.1759).
Of the drug categories tested, the "mentions per patient"
ratios of systemic corticosteroids, topical immuno-
therapy, phototherapy, contact sensitizers, and minoxidil
were significantly different between patients with tran-
sient AA and patchy AA [see Additional file 6:Table S5].
The "mentions per patient" ratios of intralesional corti-
costeroids and phototherapy were significantly different
between patients with patchy AA and AT [see Additional
file 6: Table S5]. No drug category differed in use between
patients with AT and AU.
Discussion
Our primary aim was to study current AA treatment prac-
tices across age groups and stages of progressive disease
severity. Our results suggest that children receive treat-
ment less frequently than adults. The most commonly
used AA treatments overall are corticosteroids and minox-
idil. The frequency of AA treatment decreases with pro-
gressive disease severity, and AT appears to be the "critical
point" at which there is a drop in rates of certain treat-
ments.
Our survey respondents were largely general dermatolo-
gists in suburban, solo/group private practice. The gender
distribution of respondents was 60% male/40% female.
Table 1: Other medications used for treatment of alopecia 
areata.
Treatment Number of mentions
Protopic (tacrolimus) 41
Elidel (pimecrolimus) 32
Aldara (imiquimod) 16
Cyclosporine 10
Retinoids 6
Azulfidine (sulfasalazine) 4
Amevive (alefacept) 3
Biotin 2
Dovonex (calcipotriene) 2
XTRAC laser 2
Atarax 1
Cryo spray 1
DMSO (dimethylsulfoxide?) 1
Diphencyprone** 1
Enbrel (etanercept) 1
Metronidazole 1
Multivitamin 1
Nioxin Hair Care System* 1
Rogaine (minoxidil) 1
Rogaine with Tazorac gel 1
Vytorin 1
*Does not contain any drugs, but cited by one respondent
**Respondent used in past, but now cannot obtain it.Page 4 of 8
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Table 2: Respondent demographics (N = 253; not all respondents answered demographics questions)
New AA pts per month 0 to 2 63.6%
3 to 5 29.6%
6 to 10 5.5%
11 to 20 0.4%
20+ 0.8%
Percent of new AA pts that are children None 11.5%
1 to 25 66.4%
26 to 50 17.8%
51 to 75 3.6%
76 to 99 0.4%
All 0.4%
Subspecialty certification None 88.5%
Pediatric 1.2%
Procedural 5.1%
Other 5.1%
Practice setting Solo 36.0%
Group derm only 50.2%
Multispecialty 6.3%
Academic 5.9%
Government 1.6%
Years in practice (N = 251) 0 to 5 18.3%
6 to 10 15.1%
11 to 20 26.3%
21+ 40.2%
Gender (N = 252) Male 59.9%
Female 40.1%
Location Urban 31.2%
Suburban 58.5%
Rural 6.7%
Other 3.6%
BMC Dermatology 2009, 9:11 http://www.biomedcentral.com/1471-5945/9/11Most respondents saw five or fewer new AA patients per
month. Interestingly, the majority of our respondents had
been in practice for over 10 years, and a relatively high
number (40%) had practiced for 21 years or more. The
American Academy of Dermatology (AAD) reported the
gender distribution of its members in 2007 to be 62%
male/38% female, and the 2007 AAD Practice Profile Sur-
vey (sponsored by the AAD) reported the practice settings
of a random sample of AAD members practicing derma-
tology in the U.S. to be 54.8% suburban and 44.2% solo
practice/33.1% dermatology group practice. Thus, the
demographics of our study's respondents appear to be
generally consistent with the overall demographics of U.S.
dermatologists.
We observed that respondents treated children less fre-
quently than adults, particularly in cases of patch hair
loss. Dermatologists may be less willing to treat children
due to the pain or risk associated with treatment [6]. They
may also seek to avert the patient's attention from hair
loss or to avoid social disruption [5], or to prevent a
"roller coaster of improvements and setbacks" in the
absence of proven treatments [8]. As emphasized by a
recent review, the primary limitation in evidence-based
treatment of children with AA is the lack of randomized
controlled trials of AA therapies [9]. AA is a disease with
strong potential for psychological trauma, particularly in
children [10,11], and it is important to optimize treat-
ment in this age group. Thus, some recommend that pedi-
atric patients receive counseling or join a support group
from the onset of the disease [8]. Our survey did not assess
how often physicians recommend support groups or
counseling to their patients with AA; such an assessment
would be worthwhile in the future.
Our observation that the frequency of AA treatment
decreases with progressive disease severity may similarly
reflect physician reluctance to expose patients to the risks,
costs, and side effects of treatment in the absence of
proven options. It is interesting to note that while the
number of respondents prescribing no treatment
increases with disease severity, so does the number of
respondents prescribing systemic drugs with more side
effects such as systemic corticosteroids and methotrexate.
This suggests that two different approaches to treatment
exist among dermatologists - some see a greater need to
treat with more widespread disease, while others see less
value in treatment.
Topical and intralesional corticosteroids and minoxidil
were the most commonly used treatments cited by our
respondents; however, while these drugs have frequently
been reported to be useful and successful in management
of AA, they are of questionable long-term and overall ben-
Drugs received by patients registered in the National Alopecia Areata RegistryFigure 1
Drugs received by patients registered in the National Alopecia Areata Registry. Values shown are mention rates 
with approximate 95% confidence intervals. *CS = corticosteroids. ** FK506/cyclosporine/imiquimod/pimecrolimus/other. 
***FK506/cyclosporine/other. ****PUVA/UVB. *****DNCB Dinitrochlorobenzene/diphencyprone/squaric acid dibutylesterPage 6 of 8
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controlled trials of intralesional corticosteroids, systemic
corticosteroids, or minoxidil that demonstrated clinically
significant hair regrowth [3]. The meta-analysis identified
only one trial that showed a statistically significant differ-
ence between hair regrowth with betamethasone valerate
foam and betamethasone dipropionate lotion; the study
did not include a vehicle-control arm [12]. As the authors
noted, corticosteroids and minoxidil appear to be in wide
use due to their relative safety, but their use remains
unsupported by rigorous evidence. We noted that these
drugs are used quite frequently even to treat more severe
forms of AA (AT/AU) per our survey results, though many
perceive them to be ineffective (Table 6) - again, we posit
that their relative safety and the physician's desire to offer
treatment leads to their use despite lack of evidence as to
their efficacy.
We noted that use of wigs and eyebrow tattoos for scalp
and eyebrow hair loss is limited. As it is very important to
AA patients to optimize their cosmetic appearance, more
widespread use of wigs and tattoos may be warranted.
The most commonly cited barriers to the use of various
treatments were risk of side effects; pain associated with
treatment; excessive time commitment, compliance or
cost; and lack of experience with the treatment. Interest-
ingly, lack of evidence and FDA approval were not com-
monly cited as barriers to the use of treatment. Our
findings suggest that many physicians desire to treat
despite the limited amount of available evidence, but that
many treatments are simply unsatisfactory or unfamiliar.
Data from the NAAR showed that, as suggested in our sur-
vey findings, a relatively high percentage of AA patients
never receive treatment even in the more advanced stages
of AA. NAAR data did not reveal any consistent pattern of
drug use. Even the most commonly employed treatments
(topical, intralesional, and systemic corticosteroids, topi-
cal immunotherapy, and minoxidil) show no consistent
pattern of increasing or decreasing use with progressive
stages of AA.
Limitations of our survey study include our response rate,
which was 14.6% of our target population. It is not
known whether the respondents to our survey are a repre-
sentative sample of the target population. Thus, substan-
tial "survey bias" is possible, and it is reasonable to believe
that some degree of "survey bias" is likely to be present.
We used a paper questionnaire rather than a web-based
survey format because dermatologists' e-mail addresses
for an entire region could not be obtained; our choice of
format may have skewed the demographics of our
responders. We simply defined children as "preadoles-
cents" in our questionnaire, leaving determination of an
age cutoff to the respondent; some respondents may have
defined the "preadolescent" age range differently than
others. Our survey instrument divided AA into four dis-
crete stages (first episode of patch loss vs. multiple epi-
sodes of patch loss vs. AT vs. AU) in order to simplify and
categorize physicians' treatment preferences, but within
each disease stage lies a spectrum of disease presentations
with varied prognoses that may warrant different treat-
ment approaches; these nuances may have been lost in
our study. Our survey did not ask physicians about their
diagnostic and treatment approaches for related medical
conditions such as thyroid disease.
The NAAR portion of our study was limited by our use of
the "mentions per patient" ratio; because we could not
access individual patient treatment histories, we could not
calculate percentages of patients who had used treatments
from a certain drug category (as we could not account for
cases in which a patient had received two or more drugs
from the same category). However, we were able to deter-
mine the percentages of patients who had received no
treatment over the course of their disease. The experiences
of the patients in the NAAR database may not be repre-
sentative of the experiences of all AA patients.
Our survey relied on physician recall of practice habits;
medical records were not examined for verification of
physician practices. Nonetheless, our physician-reported
findings showed good congruence with patient-reported
treatment data from the NAAR.
Conclusion
Analyses of both our survey data and patient-reported
treatment data from the NAAR lead to the conclusion that
dermatologists' treatment of pediatric and adult patients
and of progressive disease stages is inconsistent. Younger
patients and those with more severe disease appear to be
less likely to receive treatment. The acquisition of a
stronger evidence base and the development of new treat-
ments will provide better and more consistently
employed treatment options.
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